High plasma levels of factor VIII and the risk of recurrent venous thromboembolism

New England Journal of Medicine

Volumn 343, Issue 7, 2000, Pages 457-462

  Kyrle, Paul A ^a,d   Minar, Erich ^a   Hirschl, Mirko ^b   Bialonczyk, Christine ^c   Stain, Milena ^a   Schneider, Barbara ^a   Weltermann, Ansgar ^a   Speiser, Wolfgang ^a   Lechner, Klaus ^a   Eichinger, Sabine ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b HANUSCH HOSPITAL   (Austria)

^c WILHELMINEN HOSPITAL   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOPHILIA; VEIN THROMBOSIS;

FACTOR VIII; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RECURRENCE; RISK; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0034680013     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200008173430702     Document Type: Article

References (28)

1. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis
2. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: Role of increased synthesis and relationship to the acute phase reaction
3. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism
4. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase reaction
5. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions
6. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism
7. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism
8. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT): Italian Study on Complications of Oral Anticoagulant Therapy
9. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants
10. Hemorrhagic complications of anticoagulant treatment
11. Value of the ventilation/perfusion scan in acute pulmonary embolism: Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED)
12. Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with a history of venous thrombosis and criteria for rational patient screening
13. Mutation in blood coagulation factor V associated with resistance to activated protein C
14. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
15. Criteria for the diagnosis of lupus anticoagulants: An update
16. Nonparametric estimation from incomplete observations
17. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism
18. The long-term clinical course of acute deep venous thrombosis
19. The management of thrombosis in the antiphospholipid-antibody syndrome
20. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism
21. Recurrence of venous thromboembolism in patients with familial thrombophilia
22. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden
23. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene
24. The risk of recurrent venous thromboembolism in carriers and noncarriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene
25. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
26. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population. I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause
27. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism